Novel Oral Tx Shows Early Promise in Relapsed/Refractory Myeloma

(MedPage Today) -- A novel protein-degrading agent exhibited promising activity in patients with relapsed/refractory multiple myeloma, results of a preliminary clinical trial showed. Among 101 patients who received the recommended phase II dose...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news